Novo Nordisk A/S has announced an extension of its partnership with Valo Health, aimed at discovering and advancing new treatments for obesity, type-2 diabetes, and cardiovascular diseases. As part of this expansion, Novo Nordisk is committing an immediate payment of $190 million. This collaboration is projected to involve milestone payments reaching approximately $4.6 billion, along with research and development funding, and potential royalty payments.
With this expanded collaboration, Valo's Opal Computational Platform will be merged with Novo Nordisk's expertise in cardiometabolic diseases. This integration will leverage real-world patient data to drive insights, conduct clinical trials, and develop therapeutics using human-centric AI for small molecule design.
Valo will receive an upfront payment and equity investment, alongside a potential short-term milestone payment. Additionally, the company will benefit from milestone payments for up to 20 drug development programs, an increase that includes 9 new drug programs.
In early market trading, Novo Nordisk's stock is experiencing a rise of 2.84%, reaching $85.72 on the New York Stock Exchange.
The material has been provided by InstaForex Company - www.instaforex.com
With this expanded collaboration, Valo's Opal Computational Platform will be merged with Novo Nordisk's expertise in cardiometabolic diseases. This integration will leverage real-world patient data to drive insights, conduct clinical trials, and develop therapeutics using human-centric AI for small molecule design.
Valo will receive an upfront payment and equity investment, alongside a potential short-term milestone payment. Additionally, the company will benefit from milestone payments for up to 20 drug development programs, an increase that includes 9 new drug programs.
In early market trading, Novo Nordisk's stock is experiencing a rise of 2.84%, reaching $85.72 on the New York Stock Exchange.
The material has been provided by InstaForex Company - www.instaforex.com